Login to Your Account



No Vote At FDA Advisory Panel For Eyetech, Pfizer's Macugen

By Kim Coghill


Monday, August 30, 2004
ROCKVILLE, Md. - An FDA advisory panel Friday leaned toward favoring Macugen, a proposed treatment for age-related macular degeneration expected to have an impact on the aging Baby Boomer population. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription